Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The N-methyl-d-aspartate receptor (NMDAR) antagonists, phencyclidine (PCP), dizocilpine (MK-801), or ketamine, given subchronically (sc) to rodents and primates, produce prolonged deficits in cognitive function, including novel object recognition (NOR), an analog of human declarative memory, one of the cognitive domains impaired in schizophrenia. Atypical antipsychotic drugs (AAPDs) have been reported to improve declarative memory in some patients with schizophrenia, as well as to ameliorate and prevent the NOR deficit in rodents following scNMDAR antagonist treatment. While the efficacy of AAPDs to improve cognitive impairment in schizophrenia (CIS) is limited, at best, and controversial, single doses of all currently available AAPDs so far tested transiently restore NOR in rodents following scNMDAR antagonist treatment. Typical antipsychotic drugs (APDs), e.g. haloperidol and perphenazine, are ineffective in this rodent model, and may be less effective as treatments of some domains of CIS. Serotonergic mechanisms, including, but not limited to serotonin (5-HT)2A and 5-HT7 antagonism, 5-HT1A, and GABA(A) agonism, contribute to the efficacy of the AAPDs in the scNMDAR antagonist rodent models, which are relevant to the loss of GABA interneuron/hyperglutamate hypothesis of the etiology of CIS. The ability of sub-effective doses of the atypical APDs to ameliorate NOR in the scNMDAR-treated rodents can be restored by the addition of a sub-effective dose of the 5-HT1A partial agonist, tandospirone, or the 5-HT7 antagonist, SB269970. The mGluR2/3 agonist, LY379268, which itself is unable to restore NOR in the scNMDAR-treated rodents, can also restore NOR when given with lurasidone, an AAPD. Enhancing cortical and hippocampal dopamine and acetylcholine efflux, or both, may contribute to the restoration of NOR by the atypical APDs. Importantly, co-administration of lurasidone, tandospirone, or SB269970, with PCP, to rodents, at doses 5–10 fold greater than those acutely effective to restore NOR following scNMDAR treatment, prevents the effect of scPCP to produce an enduring deficit in NOR. This difference in dosage may be relevant to utilizing AAPDs to prevent the onset of CIS in individuals at high risk for developing schizophrenia. The scNMDAR paradigm may be useful for identifying possible means to treat and prevent CIS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 1×
“An inverted U-shape dose response curve was found for SKF38393, as has been observed with other procognitive effects of D1 agonists (Goldman-Rakic et al., 2004).”
BackgroundThe Declarative/Procedural Model of Lexicon and Grammar
Ullman, M. T. (2001) · Journal of Psycholinguistic Research · doi:10.1023/a:1005204207369 · Cited by 508 · cited 1×
“Recognition memory, as well as long term verbal memory, is known to involve the hippocampus, the retrosplenial and perirhinal cortex and the prefrontal cortex (PFC) (Ullman, 2001).”
BackgroundRole of serotonin in memory impairment.
Buhot, M.-C., Martin, S., & Segu, L. (2000) · Annals of Medicine · doi:10.3109/07853890008998828 · Cited by 419
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
The 5-HT7 receptor and disorders of the nervous system: an overview
Hedlund, P. B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1626-0 · Cited by 239 · cited 1×
“It is expressed in brain regions, including the thalamus, limbic regions, hippocampal formation, and frontal cortex, that are involved in psychosis, learning and memory (To et al., 1995; Hedlund, 2009; Roberts and Hedlund, 2012).”
BackgroundRapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · cited 1×
“The 5-HT2A receptor is the most abundant 5-HT receptor subtype in the cortex (Jones et al., 2009) and has been shown to play a key role in the transport and dynamic regulation of NMDARs in cortical pyramidal neurons (Yuen et al.”
BackgroundSerotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism
Yuen, E. Y. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1187-05.2005 · Cited by 225 · cited 1×
“, 2009) and has been shown to play a key role in the transport and dynamic regulation of NMDARs in cortical pyramidal neurons (Yuen et al., 2005).”
BackgroundAbdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206
Cited by
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Jett, J. D., Boley, A. M., Girotti, M., Shah, A., Lodge, D. J., & Morilak, D. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3957-3 · Cited by 75
“In healthy humans and rodent models, this ketamineinduced hyper-glutamatergic state has been associated with psychotic-like behaviors and cognitive impairments characteristic of schizophrenia (Krystal et al. 1994; Moghaddam and Javitt 2012; Meltzer et al. 2013; Schobel et al. 2013).”
Janhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“…reproduced with permission from Frontiers in Psychiatry receptor (Redrobe et al. 2012), a nicotinic α7 acetylcholine receptor agonist (McLean et al. 2011), a choline uptake enhancer (Shirayama et al. 2007) and a 5-HT6 receptor antagonist (Arnt et al. 2010) (for a review see Meltzer et al. 2013).”
BackgroundMcLean, S. L., Harte, M. K., Neill, J. C., & Young, A. M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117704988 · Cited by 16
“The non-competitive NMDA receptor antagonist PCP has been shown to produce enduring cognitive deficits similar to those observed in schizophrenia in rodents (Javitt and Zukin, 1991; Meltzer et al., 2013), particularly when administered sub-chronically (sc) (Janhunen et al.”
BackgroundNeugebauer, N. M., Miyauchi, M., Sato, T., Tadano, J., Akal, H., Ardehali, H., & Meltzer, H. Y. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.033 · Cited by 7
“NMDA receptor hypofunction is commonly induced in animal models of CIAS by the sub-chronic (sc) administration of the NMDA receptor antagonist, PCP, leading to persistent impairment in cognitive tasks that are analogous to those in schizophrenia patients, including novel object recognition (NOR) [20].”
Self-citation
Metadata
- Authors
- Meltzer, H. Y., Rajagopal, L., Huang, M., Oyamada, Y., Kwon, S., & Horiguchi, M.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-01
- Volume
- 16
- Issue
- 10
- Pages
- 2181-2194
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2090246683
- Cited by
- 113
- References
- 18
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. https://app.cochat.ai/papers/10.1017/s1461145713000928
- The paper
- Meltzer, H. Y., Rajagopal, L., Huang, M., Oyamada, Y., Kwon, S., & Horiguchi, M. (2013). Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145713000928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.